Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
UPDATE: Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Neutral
-
Chardan Capital Sees New Reasons Regeneron (REGN) Praluent Could be Bemoved from the US Market in 2016
-
Notable Analyst Rating Changes 6/13: (ENDP) (NGL) (CVE) Upgraded; (GSAT) (LYB) (HCLP) Downgraded
-
UPDATE: Chardan Capital Markets Downgrades Globalstar (GSAT) to Neutral
-
AB Science will hold an Investor & Analyst conference on masitinib in Amyotrophic Lateral Sclerosis (ALS) in New York, USA, on June 13, 2016
-
UPDATE: Chardan Capital Markets Downgrades Adverum Biotechnologies (ADVM) to Neutral
-
Covata Completes AU$13.2 Million Private Placement of Common Stock to U.S. and Asia-Pac Institutional Investors
-
Chardan Capital Markets Downgrades KVH Industries (KVHI) to Neutral
-
Unusual 11 Mid-Day Movers 5/24: (SPEX) (XCO) (APHB) Higher; (CLRB) (DSW) (UNIS) Lower
-
Notable Analyst Rating Changes 5/24: (SQ) (MSFT) (DE) Upgraded; (TWTR) (CF) (CYH) Downgraded
-
Pre-Open Stock Movers 05/24: (MGN) (XCO) (PLCM) (GPRO) Higher; (SSW) (DSW) (SAGE) (BBY) Lower (more...)
-
Chardan Capital Markets Starts Sage Therapeutics (SAGE) at Sell
-
Form REVOKED CHARDAN CHINA ACQUISITIO
-
Chardan Capital Markets Starts Asterias Biotherapeutics (AST) at Buy
-
UPDATE: Chardan Capital Markets Starts Arrowhead Research (ARWR) at Buy
-
Inventergy Raises $1.3 Million in a Registered Direct Offering
-
VistaGen Completes $10 Million Public Offering
-
UPDATE: Notable Analyst Rating Changes 5/16: (NOK) (JCP) (BBT) Upgraded; (DB) (BLOX) (BITA) Downgraded
-
Chardan Capital Markets Starts Arbutus Biopharma (ABUS) at Sell
-
VistaGen Announces Nasdaq Listing and Pricing of $10.0 Million Public Offering
-
Jensyn Acquisition Corp. Announces Termination of Over-Allotment Option and Common Stock, Rights and Warrants to Commence Separate Trading on or about April 25, 2016
-
Amarantus Announces Capital Infusion
-
The PIPEs Report Sees Small-Cap Equity Financing Growth at the End of Q1 2016
-
Chardan Capital Markets Starts Emergent BioSolutions (EBS) at Buy
-
Majesco Entertainment (COOL) Entesr $1.5M Registered Direct Offering
-
Majesco Entertainment Announces Above Market Registered Direct Offering
-
Spark Therapeutics (ONCE) Patent Concerns are Resolving - Chardan Capital Markets
-
Chardan Capital Markets Starts Regulus Therapeutics (RGLS) at Buy, $15 PT
-
Pre-Open Stock Movers 04/12: (FOLD) (ARNA) (HLX) Higher; (HZNP) (OZM) (JNPR) Lower (more...)
-
MassRoots (MSRT) Looks to Become First Cannabis-Related Stock Listed on the Nasdaq with IPO Filing
-
Cemtrex (CETX) Announces Filing of S-3 Registration Statement
-
Caesarstone Sdot-Yam (CSTE) on Watch as Kibbutz Sdot Yam Could Sell Its Entire Stake
-
Amicus Therapeutics (FOLD) Could Be Worth More Than $22.50/Share in a Takeout - Chardan Capital
-
PlacementTracker Publishes Q1 2016 PIPE Market League Tables
-
Chardan Capital Markets Starts CaesarStone Sdot-Yam (CSTE) at Buy
-
Chardan Capital Markets Starts Dicerna Pharmaceuticals (DRNA) at Neutral
-
Chardan Capital Markets Starts Alnylam Pharmaceuticals (ALNY) at Buy
-
Chardan Capital Markets Starts Novavax (NVAX) at Neutral
-
Notable Analyst Rating Changes 3/28: (PRXL) (FINL) (THG) Upgraded; (XONE) (PH) (ATW) Downgraded
-
Chardan Capital Markets Starts AveXis (AVXS) at Buy
-
Green Shoots in uniQure (QURE) POC Data - Chardan Capital Markets
-
The Medicines Company (MDCO) PT Lifted to $65 at Chardan Capital Markets
-
Chardan Capital Markets Downgrades Regeneron Pharma (REGN) to Sell
-
StemCells, Inc. Announces Closing of $8 Million Public Offering
-
Energous (WATT) Catalysts To Profitability Begin In 2Q16 - Chardan Capital Markets
-
Chardan Capital Markets Downgrades BCommunication Ltd. (BCOM) to Neutral
-
StemCells (STEM) Prices $11M Stock, Warrants Offering
-
StemCells, Inc. Announces Pricing of Public Offering to Raise $8.1 Million
-
Jensyn Acquisition Corporation Completes $39.0 Million Initial Public Offering
-
Chardan Capital Markets Cuts Price target on Ambarella (AMBA) to $50 as Growth Continues to Slow

